Zenlabs Ethica Limited (ZENLABS) Share Price

BSE · Healthcare · Medical Distribution · ISIN INE546F01013

₹29.00+1.42 (+5.15%)

Key metrics

Market Cap
₹19 Cr
P/E Ratio
EPS
-3.9
Book Value
13.08
P/B Ratio
2.11
ROE
-22.73%
ROCE
4.57%
Debt / Equity
1.29
Net Margin
-4.13%
Revenue Growth
-8.75%
Profit Growth
-819.02%
Dividend Yield
52W High
₹39.99
52W Low
₹16.50
Market Cap Band
micro cap
Face Value

Ratios computed from the annual results period ending 2026-03-31.

About Zenlabs Ethica Limited

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, Bangladesh, and internationally. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016. Zenlabs Ethica Limited was incorporated in 1993 and is based in Chandigarh, India.

Headquarters
Chandigarh, India
Promoter Holding
66.23%

The full Zenlabs Ethica Limited analysis

Create a free account to open the complete ZENLABS deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.